Vimarsana
Biggest News Aggregation in the World

Page 8 - Invo Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Invo Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Invo Bioscience Today - Breaking & Trending Today

Reviewing InVivo Therapeutics (NASDAQ:NVIV) and Invo Bioscience (OTCMKTS:IVOB) - Vimarsana News

Reviewing InVivo Therapeutics (NASDAQ:NVIV) and Invo Bioscience (OTCMKTS:IVOB)

Invo Bioscience (OTCMKTS:IVOB – Get Rating) and InVivo Therapeutics (NASDAQ:NVIV – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk. Insider and Institutional Ownership 18.6% of InVivo Therapeutics shares […]

INVO Bioscience, Inc. (NASDAQ:INVO) Short Interest Up 22.5% in May - Vimarsana News

INVO Bioscience, Inc. (NASDAQ:INVO) Short Interest Up 22.5% in May

INVO Bioscience, Inc. (NASDAQ:INVO – Get Rating) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 71,800 shares, an increase of 22.5% from the April 30th total of 58,600 shares. Based on an average trading volume of 38,800 shares, the […]

INVO Bioscience (NASDAQ:INVO) Lifted to Buy at Zacks Investment Research - Vimarsana News

INVO Bioscience (NASDAQ:INVO) Lifted to Buy at Zacks Investment Research

INVO Bioscience (NASDAQ:INVO – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday, Zacks.com reports. The firm currently has a $1.25 target price on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 16.28% from the stock’s current […]

INVO Bioscience (NASDAQ:INVO) Lowered to "Hold" at Zacks Investment Research - Vimarsana News

INVO Bioscience (NASDAQ:INVO) Lowered to "Hold" at Zacks Investment Research

INVO Bioscience (NASDAQ:INVO – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday, Zacks.com reports. According to Zacks, “INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. […]

Maxim Group Lowers INVO Bioscience (NASDAQ:INVO) Price Target to $3.00 - Vimarsana News

Maxim Group Lowers INVO Bioscience (NASDAQ:INVO) Price Target to $3.00

INVO Bioscience (NASDAQ:INVO – Get Rating) had its price target lowered by stock analysts at Maxim Group to $3.00 in a report issued on Thursday, Stock Target Advisor reports. Maxim Group’s price objective points to a potential upside of 200.00% from the company’s current price. INVO has been the subject of a number of other […]